Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

2'-cyano-2'-deoxyarabinofuranosylcytosine

Known as: 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine, 2'-cyano-2'deoxy-1-beta-D-arabinofuranosylcytosine, CNDAC 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Cytarabine

Narrower (1)

Nucleoside Analog DFP-10917
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2005
2005
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is a nucleoside analogue with a novel mechanism of action… Expand
Highly Cited
2004
Highly Cited
2004
Anti‐neovascular therapy by liposomal drug targeted to membrane type‐1 matrix metalloproteinase
Because membrane type‐1 matrix metalloproteinase (MT1‐MMP) is expressed specifically on the angiogenic endothelium as well as… Expand
Review
2004
Review
2004
Antitumor activity of sugar‐modified cytosine nucleosides
Nucleoside analogues which show antimetabolic activity in cells have been successfully used in the treatment of various tumors… Expand
Highly Cited
2002
Highly Cited
2002
Anti‐neovascular therapy by liposomal DPP‐CNDAC targeted to angiogenic vessels
We previously reported that liposomalized 5′‐O‐dipalmitoylphosphatidyl 2′‐C‐cyano‐2′‐deoxy‐1‐β‐D‐arabino‐pentofuranosylcytosine… Expand
Highly Cited
2001
Highly Cited
2001
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
The mechanism of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human… Expand
Highly Cited
1999
Highly Cited
1999
Antitumor activity and novel DNA‐self‐strand‐breaking mechanism of CNDAC (1‐(2‐C‐cyano‐2‐deoxy‐β‐d‐ARABINO‐Pentofuranosyl) cytosine) and its N4‐palmitoyl derivative (CS‐682)
We have studied the antitumor activity and the novel DNA‐self‐strand‐breaking mechanism of CNDAC (1‐(2‐C‐cyano‐2‐deoxy‐β‐d… Expand
1995
1995
Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1…
We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand… Expand
Highly Cited
1993
Highly Cited
1993
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
Design, synthesis, and tumor cell growth inhibitory effects of 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl derivatives of… Expand
Highly Cited
1992
Highly Cited
1992
Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
The antitumor effects of 2'-C-cyano-2'-deoxy-1-beta-D- arabinofuranosylcytosine (CN-DAC), a synthetic 1-beta-D-arabinofuranosyl… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE